A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Phase 2
78
about 4.7 years
18+
7 sites in CA, MI, NC +3
What this study is about
Researchers are testing whether itraconazole, an anti-fungal medication, can help people with esophageal cancer achieve a complete response after surgery. The trial will involve adding itraconazole to standard treatment for esophageal and gastroesophageal junction cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Itraconazole
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
itraconazole (Antifungal; inhibits ergosterol synthesis)
oral (Oral Capsule)
Secondary: Determine the utility of ctDNA and exosome characterization as a prognostic marker
Oncology